Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9580237 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL8608486 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL5879075 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL29067690 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL5879043 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL630334 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL28953563 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL5878852 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL8133996 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD | |
| SCHEMBL27642501 | 1.00 | GPR84 (0.62) | GPR84FFAR1FFAR4LMNAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317796-A | EGFRvIII targeting compounds and uses thereof | 加拿大国立研究院 | 2024-07-09 | — | — | CN | claimed |
| CN-116635408-A | Reactive conjugates | 德彪药业国际股份公司 | 2023-08-22 | — | — | CN | claimed |
| CN-118317796-A | EGFRvIII targeting compounds and uses thereof | 加拿大国立研究院 | 2024-07-09 | — | — | CN | disclosed |
| CN-118302433-A | Fibronectin binding peptides for diagnosis and treatment of tumors or fibrosis | 苏黎世联邦理工学院 | 2024-07-05 | — | — | CN | disclosed |
| CN-118159305-A | Radioactive complexes and radiopharmaceuticals of deglycosylated antibodies | 日本医事物理股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118119406-A | Combination radiation therapy | 泰利斯制药(创新)有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118043482-A | Methods for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a CCK2-R targeting compound, and compounds for use in methods for selectively treating and/or imaging cancer | 保罗·谢勒学院 | 2024-05-14 | — | — | CN | disclosed |
| CN-113993547-B | Use of bispecific antigen binding molecules binding MUC16 and CD3 in combination with 4-1BB costimulation | 瑞泽恩制药公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114025802-B | Use of bispecific antigen binding molecules binding to PSMA and CD3 in co-stimulatory combinations with 4-1BB | 瑞泽恩制药公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-110650974-B | Radiolabeled anti-LAG 3 antibodies for immune-PET imaging | 瑞泽恩制药公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024044551-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-116456992-A | Radioactive complexes and radiopharmaceuticals of anti-HER 2 antibodies | 日本医事物理股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116390766-A | Process for producing radioactive zirconium complex | 日本医事物理股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115304582-B | FAP-alpha specific tumor diagnostic imaging agent | 北京法伯新天医药科技有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-109789207-B | Targeted radiotherapeutic chelates for in situ immunomodulating cancer vaccination | 威斯康星校友研究基金会 | 2022-11-18 | — | — | CN | disclosed |
| CN-115304582-A | FAP-alpha specific tumor diagnosis imaging agent | 北京法伯新天医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114585393-A | RI-labeled humanized antibodies | 日本医事物理股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114555132-A | Method for producing radiometal-labeled antibody | 日本医事物理股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021075544-A1 | RI-LABELED HUMANIZED ANTIBODY | 日本メジフィジックス株式会社 | 2021-04-22 | — | — | WO | disclosed |
| CN-111565762-A | Use of Targeted Radiotherapy (TRT) to drive an anti-tumor immune response to immunotherapy | 威斯康星校友研究基金会 | 2020-08-21 | — | — | CN | disclosed |